Objectives-We evaluated the ability of third-trimester ultrasonography (US) to diagnose disorders of fetal growth among women with diabetes mellitus.
D
ue to the obesity epidemic, the proportion of pregnant women with either pregestational or gestational diabetes in pregnancy has increased in recent years. 1, 2 Women with gestational and pregestational diabetes are at increased risk of delivering a large-for-gestational age (LGA) neonate. 3 Diabetes and LGA fetuses are independent risk factors for a number of obstetric complications at the time of delivery, including shoulder dystocia, 4 higherorder perineal lacerations, 5 and cesarean delivery. 6 Thus, most women with diabetes undergo ultrasonography (US) to assess fetal weight in the third trimester to assist with delivery planning.
Several technical challenges to the accuracy US often exist in the diabetic pregnant patient. Ultrasonography is known to be less accurate with increasing fetal weight 7 and at later gestational ages (GAs).
Many women with diabetes are also obese; maternal adiposity poses a challenge to an accurate US estimated fetal weight. 9 Much previous literature on US in the diabetic population focused on detection of macrosomia, with most studies showing that US performed relatively poorly in accurately detecting macrosomia. 7 Overdiagnosis of macrosomia can lead to unindicated elective cesarean delivery or other interventions. 10 Moreover, the diagnostic ability of US to detect the small-forgestational-age (SGA) status among women with diabetes remains unclear.
Given these challenges but yet the common frequency of US in this population, it is important to understand the test characteristics of US for estimated fetal weight in this population. Additionally, it is unclear from previous studies whether the type of diabetes (gestational versus preexisting) affects the diagnostic accuracy of US to detect macrosomia. Thus, in this study, we used a large tertiary care center cohort to characterize the diagnostic capability of third-trimester US to detect LGA and SGA fetuses in pregnant women with diabetes and to determine whether there are differences in test characteristics by the type of maternal diabetes.
Materials and Methods
This work was a retrospective cohort study of women aged 18 years or older with gestational or pregestational diabetes who delivered term (37.0 weeks' gestation) singleton gestations and received US examinations at Northwestern Memorial Hospital in Chicago, Illinois, between January 1, 2010, and December 31, 2015. Approval for this study was obtained from the Northwestern Institutional Review Board with a waiver of informed consent. Women were included in the study if they had a US examination performed for a fetal weight estimate within 5 weeks of delivery. Women were excluded if they had a fetus with a major anomaly, as that may impair accurate measurement of fetal weight. Women who had US examinations performed solely for a biophysical profile, fluid volume, or fetal presentation but without assessment of estimated fetal weight were excluded. Women who had informal "bedside" US examinations that were not read by the Division of Maternal-Fetal Medicine were also excluded. Clinical and demographic data were abstracted from the electronic medical record and US database, including information on estimated fetal weight and ultimate birth weight.
All US examinations were performed by trained sonographers calculating estimated fetal weight using formula of Hadlock et al, 11 incorporating head circumference, biparietal diameter, abdominal circumference, and femur length. For the purposes of consistent terminology, the phrases SGA and LGA refer to both fetuses and neonates at the extremes of growth, as terms such as "macrosomia" do not have consistently accepted definitions. We defined fetuses as SGA if the US estimated fetal weight was less than 10% for GA at the time of US using the percentiles generated by Brenner et al 12 and embedded into the AS US software package (AS Software, Inc, Englewood Cliffs, NJ) and the corresponding neonate as SGA if birth weight was less than 10% for GA at birth, using standardized growth curves for birth weights in the United States generated by Oken et al. 13 Similarly, we defined fetuses as LGA if the US estimated fetal weight was greater than 90% for GA at the time of US and the corresponding neonate as LGA if birth weight was greater than 90% for GA at birth, again using the values of Brenner et al 12 for fetal growth curves and the standardized values generated by Oken et al 13 for neonatal growth percentiles.
We defined different types of gestational diabetes by using the White criteria, 14 with A1 gestational diabetics as those who were diet controlled during pregnancy and A2 gestational diabetics as those who that required medication.
14 Women with pregestational diabetes were classified as either type 1 or type 2 using the diagnoses made before pregnancy according to patients' previous primary care physicians or endocrinologists; however, our institution follows recommended guidelines for early screening and diagnosis of type 2 diabetes during pregnancy. 15 Patient demographic and clinical characteristics were compared by type of diabetes. We calculated the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of a US examination performed within 5 weeks of delivery to detect SGA and LGA neonates for the overall sample, as well as for each type of diabetes. We also calculated the receiver operating characteristic curve (ROC) associated with each type of diabetes, comparing the area under the curve (AUC) to see whether diagnostic performance varied across types of diabetes. The AUC values associated with different types of diabetes were compared for equality by the methods suggested by DeLong et al. 16 To determine the consequences of antenatal LGA and SGA diagnoses based on US estimated fetal weight, we also examined neonatal outcomes, including admission to the neonatal intensive care unit, shoulder dystocia, and third-and fourth-degree perineal laceration. We performed bivariable comparisons of neonatal outcomes based on the weight category (SGA, appropriate-forgestational-age [AGA], or LGA) using a v 2 square analysis and the Fisher exact test. Comparisons were considered statistically significant at the P < .05 level for 2-sided hypotheses. All analyses were performed with Stata version 14.2 software (StataCorp, College Station, TX).
Results
Of 877 women with diabetes who otherwise met the study inclusion criteria, 521 (59.5%) had a US examination within 5 weeks of delivery and constituted the population of interest. In this population, 3 women (0.6%) screened positive for SGA, and 64 (12.3%) delivered an SGA neonate. Thus, the overall sensitivity of US for SGA was 4.7%, and specificity was 100%. In contrast, 129 (24.8%) screened positive for LGA, and 61 (11.7%) delivered an LGA neonate. The overall sensitivity of US for LGA was 80.3%, and the specificity was 82.6%. The overall AUC values were 0.82 for LGA and 0.52 for SGA. Table 1 shows there were no significant differences in demographic or obstetric characteristics between women whose fetuses had an accurate diagnosis compared with those who ultimately delivered a fetus in a different birth weight class than that predicted by US.
In assessing test characteristics by the type of diabetes (Table 2) , we found that the sensitivity of US for the detection of LGA was lowest for women with type 2 diabetes mellitus (57.1%) and highest for women with type 1 diabetes mellitus (94.7%). In contrast, the specificity of US for LGA was greatest for women with A1 gestational diabetes (85.6%) and lowest for women with type 1 diabetes (68.6%). The PPV of US for LGA was less than 40% for all women except for those with type 1 diabetes, whereas the NPV for LGA approached 100% for all women. With regard to the SGA status, the sensitivity Data are presented as mean 6 SD and number (percent). a Accurately and inaccuratly refer to whether the predicted birth weight category (SGA, AGA, or LGA) based on the US estimated fetal weight was concordant with the actual birth weight category (SGA, AGA, or LGA).
of US for SGA was universally poor, whereas the specificity was universally 100%. The PPV and NPV for SGA were high for women with all types of diabetes. Figure 1 shows the ROC characteristic curve for each type of diabetes in the detection of LGA. The ROC curves for the detection of LGA did not differ significantly by the type of diabetes (P 5 .68). Furthermore, adding the type of diabetes to the predictive model did not improve the ability of US to detect LGA (P 5 .07). Given the overall poor performance of US for diagnosing SGA, we did not compare ROC curves across types of diabetes for SGA.
Of the 389 women with fetuses determined to be AGA on US, 61 (15.7%) ultimately delivered an SGA neonate, and 12 (3.1%) delivered an LGA neonate. Of the 61 SGA neonates incorrectly identified as AGA on US, 19 (31.2%) were admitted to the neonatal intensive care unit, compared with 67 (21.2%) of the appropriately grown neonates (P 5 .09). Of the 12 women whose fetuses were identified as AGA but ultimately delivered LGA neonates, 5 delivered vaginally. Of these 5 women, 2 (40.0%) had a third-degree laceration, compared with 8 (4.3%) of 185 women who were identified on US as having an AGA fetus and ultimately delivered an AGA fetus (P < .001). Of these 5 women, 1 (20.0%) had shoulder dystocia, compared with 7 (3.6%) of women with AGA fetuses/neonates (P 5 .07). Of the 5 women who delivered vaginally, all 5 delivered a neonate weighing greater than 4000 g, but only 1 woman delivered a neonate weighing greater than 4500 g.
Discussion
Women with diabetes often undergo growth US in the third trimester to aid in glycemic control and delivery planning. 17 However, the diagnostic accuracy of US for estimated fetal weight in women with diabetes, for whom there is greater risk of an LGA status but also a potentially greater risk of errors in US measurements, has not been well described. We characterized the diagnostic accuracy of US to detect fetal growth disorders, namely SGA and LGA, in a diverse population of women with both gestational and pregestational diabetes. Similar to other studies in older cohorts and in women without diabetes, 7,18-20 the PPV of growth US for LGA in this population was low. This study confirms that the primary value of third-trimester growth US may be to rule out LGA. Women in this study who delivered an LGA fetus who was missed on prenatal diagnosis were more likely to have shoulder dystocia and a third0-degree perineal laceration, although only 1 of these neonates would have met the antepartum criteria of 4500 g for a primary cesarean delivery. 21 A novel finding in this analysis was the low sensitivity of US for SGA in this sample of diabetic patients, which was considerably worse than in nondiabetic pregnancies. [22] [23] [24] The underdiagnosis of SGA neonates in this population is concerning. Although maternal diabetes is classically associated with fetal overgrowth, women with diabetes, particularly those with longstanding vascular disease, remain at risk of developing intrauterine growth restriction, 25 leading to an SGA neonate. Such a risk can be compounded in the context of other risk factors for growth restriction, including inadequate gestational weight gain, 26 hypertension, and renal disease. 27 These neonates are at higher risks of stillbirth, neonatal morbidity, and neonatal mortality. 28 A recent study among women with uncomplicated pregnancies indicates that SGA fetuses who are not properly diagnosed and monitored are at higher risks of stillbirth, neonatal mortality, and neonatal morbidity. 28 Although most women in this population are already undergoing antenatal testing with either biophysical profiles or nonstress tests due to maternal diabetes, monitoring specific to intrauterine growth-restricted fetuses, such as Doppler US of the umbilical artery, would not be performed. As clinicians likely have a higher index of suspicion for macrosomia, rather than intrauterine growth restriction, in this population, a substantial number of SGA neonates may be missed despite frequent growth US examinations, an assertion that could be tested in other diabetic cohorts.
The strengths of this analysis include the study of a large cohort of women with multiple subtypes of diabetes. All US examinations were performed at a single institution by a small number of highly trained obstetric sonographers, with the examinations read by a discrete group of maternal-fetal medicine physicians. However, this study also had several limitations. First, the number of fetuses screening positive for SGA was low, which may have made estimates of test characteristics unstable. Second, not all diabetic patients at our institution undergo third-trimester growth studies (especially women with A1 gestational diabetes); thus, there may have been a selection bias in who underwent US, although presumably women at greatest risk of having LGA fetuses were the most likely to undergo a scan. Third, these results may not be generalizable to a broader population, as this study was performed at a tertiary care academic medical center, with highly trained obstetric sonographers. Finally, our study was underpowered to detect significant differences in rare adverse outcomes such as shoulder dystocia, as well as differences in the AUC values for different ROC curves based on different subtypes of diabetes.
In summary, although US for estimated fetal weight in the third trimester is commonly performed for women with gestational or pregestational diabetes, the test characteristics of such an US examination suggest that these estimates are far from perfect. Specifically, whereas US had a high NPV for LGA, the sensitivity, specificity, and PPV for LGA were suboptimal. Moreover, the ability to detect LGA did not differ by the type of diabetes, although again, our study was likely underpowered to detect such differences. Further work is required to understand how clinicians can optimize the performance of US, such as by specific growth curves or other alterations in US performance, for this population. 
